BioCina and Nova Cina, two Australian CDMOs, have announced a strategic merger which will see the companies operate under the BioCina name. The merger is intended to strengthen the biopharmaceutical and small molecule brand, with the company focusing on cell line development, process development, clinical and commercial drug production and sterile fill-finish of such products.

The merger will leverage BioCina’s expertise in process development and manufacturing of the microbial, plasmid DNA and mRNA products at the Adelaide, South Australia facility. This will integrate with NovaCina’s Perth, Western Australia facility; a sterile fill-finish plant that has produced more than 600 biologic and small molecule products.